Blog

Category Archives: New Tests

MNG announces the MNG Xpress Exome™

MNG is pleased to announce the availability of the MNG Xpress Exome™ with results in 10-14 days, and exciting updates to the MNG Exome™

Exome sequencing is a powerful diagnostic tool that has proven clinical utility to identify mutations in Mendelian disorders that are both genetically and phenotypically heterogeneous. For clinical situations that demand the fastest turnaround time, MNG is pleased to offer the MNG Xpress Exome™ with results in 10-14 days. Most labs offer a premium cost for a STAT result, but MNG offers this service at an economical cost of $4,895 for Trio testing and $3,295 for Proband only testing.



The Value of Reanalysis

As whole exome sequencing (WES) becomes more routinely used for the diagnosis of genetic disorders, MNG recognizes the importance of routine reanalysis of previously generated WES data. With our knowledge of genetics and bioinformatics growing rapidly, MNG plans to stay on top of these improvements and make keeping up with the latest information as easy as possible to assist with patient care.

Effective immediately, any MNG Exome™ (including Xpress) ordered in the past or future will be eligible for full reanalysis 6 months after the issuance of the initial report, and once per 12 month period thereafter. All data will be re-evaluated, not just classification updates to previously reported variants, including copy number changes and newly identified variants. Please feel free to call or email us for any additional details.

The MNG Exome™ is already trusted as the most comprehensive and fastest exome available with a TAT of 2-4 weeks. We are pleased to announce a more economical price for an MNG Exome™ Trio at $4,395 and Proband only at $2,795. The MNG Exome™ includes 100% coverage of expert approved variants, copy number analysis, mtDNA sequencing + deletion and heteroplasmy assessment, and detection of uniparental disomy.

Read more about our MNG Exome™ on our website.

Now Introducing the MNGenome®

MNG is proud to announce the launch of the MNGenome®. This new test sequences the entire human genome, making it our most comprehensive clinical diagnostic test ever. The MNGenome® provides greater sensitivity than whole exome sequencing, since approximately 20% of known pathogenic variants are outside the exon boundaries. The MNGenome® is a comprehensive approach to diagnosis when faced with challenging phenotypes, and no diagnosis with CMA and whole exome sequencing.

To read the full press release, click here.

 

Introducing the MNG Xpress™ Actionable Epilepsy Panel

MNG is now launching the MNG Xpress™ Actionable Epilepsy panel with a standard STAT turnaround time of < 2 weeks at no additional cost and with no additional requisition forms to fill out. Our Actionable Epilepsy panel is now always STAT. You know MNG as your source for Neurogenetic Answers™ and we pride ourselves on delivering actionable results you can count on. For patients you suspect have an epilepsy phenotype and you are looking for genetic results that may have an actionable outcome, you need those results STAT. At 69 genes, our MNG Xpress™ Actionable Epilepsy panel contains a targeted list of epilepsy and seizure related genes – those that are actionable via seizure medications, pharmacological interventions, and dietary changes. For a full list of the actionable genes and therapies in our MNG Xpress™ Actionable Eilepsy panel click here. Our complete Epilepsy portfolio contains several flexible options to fit your patient’s needs:

Now Introducing RNA Sequencing Services

MNG Transcriptome™ is a cutting-edge, powerful analysis tool using RNA sequencing to determine what effect, if any, a VUS may have on the transcription of RNA from DNA, especially those found in splice site regions. This analysis is commonly used in cancer diagnostics, but can be applied to any phenotype to assess the functional impact of a variant on gene expression. MNG understands that our clients are looking for answers and sometimes the answer to the most challenging diagnostic cases require the most sophisticated tools. The MNG Transcriptome™ is now available and we believe will become a valuable added feature to our growing portfolio. There are three ways to use MNG’s expertise in RNA sequencing, all with 2-4 week turnaround time:
  1. MNG Transcriptome – Full Analysis: Complete RNA transcriptome sequencing that can be ordered at the time of initial testing as a reflex to any NGS panel, or in conjunction with our MNG ExomeTM.
  2. Gene-Specific RNA Sequencing: Analysis of one or up to five genes for variant investigation following a report with a VUS identified in a splice site or intronic region, or the variant is noted to have a potential effect on splicing.
Exclusive to MNG panels, we provide services to the following:
  1. Panel-Specific RNA Sequencing: Transcriptome analysis can be ordered as an add-on to any of our NGS panels and will only include the analysis of genes listed in the panel.
These tests have been validated on the following tissue types:
  • Blood
  • Muscle biopsies
  • Fibroblasts and lymphoid cell lines
Please call MNG Laboratories prior to ordering transcriptome testing due to its clinical relevance to the patient, which tissue type is required, and logistical coordination of sending a specimen for RNA extraction which requires a separate specimen collection process.

MNG Laboratories Adds the Most Comprehensive Neuropathy Panel to Their Extensive Portfolio of Hereditary Neuropathy Testing

At MNG Laboratories, our goal is to ensure that our test offerings continue to stay at the forefront of genetics. We are excited to announce significant improvements to our neuropathies portfolio.
Our neuropathies portfolio now includes a Comprehensive Neuropathies Panel that includes 629 genes and 14,750 pathogenic variants associated with conditions linked to hereditary neuropathies. This panel includes mtDNA sequencing and deletion analysis, and deletion/duplication of nuclear genes to provide you with the most comprehensive testing possible.
With our Neuropathy portfolio expansion, adding genes doesn’t always mean adding cost. See below for new lower test costs in our Charcot-Marie Tooth portfolio: All of our next-generation sequencing panels include single-exon resolution copy number analysis to provide you the most clinically sensitive testing possible.

Fragile X Repeat Expansion Testing Now Available

At MNG Laboratories, we continuously seek ways to improve our diagnostic abilities and to stay at the forefront of the genetics field. MNG is proud to announce the availability of Fragile X repeat expansion testing within our portfolio of recognized diagnostic tests. We’d also like to recognize this launch in light of July being National Fragile X Awareness Month. You can read more about this at the National Fragile X Foundation’s website. Fragile X is the most common cause of inherited intellectual disability and can be seen in both males and females with a range of symptomatic characteristics. The main cause of Fragile X Syndrome is the repeat expansion region of CGGs in the FMR1 gene resulting in a lack of protein (FMRP) essential for normal cognitive development. The number of repeats correlates to the severity of symptoms, especially in males, and is often linked with Autism Spectrum Disorders. To complement our Fragile X Repeat Expansion testing, MNG includes methylation analysis where clinically relevant. When >200 repeats are discovered, this triggers methylation of FMR1 and stops any synthesis of the fragile X protein, resulting in a complete lack of gene function. While this is a positive feature in females enabling them to use their second healthy copy of FMR1, methylation results in a fully expressed mutation in males and a higher severity of symptoms. Since Fragile X repeat expansions cannot be detected by NGS sequencing alone, we have added Fragile X Repeat Expansion + Methylation Analysis to our Comprehensive Intellectual Disability and X-Linked Intellectual Disability Panels. Our Intellectual Disability portfolio is now better than ever: We strive to give you the best answers possible when you trust us with your patients’ samples. MNG constantly endeavors to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.

Order Your Next Test

Updates to Selected NGS Panels

MNG Laboratories announces content updates to several next-generation sequencing panels based on recent ClinVar data. All of our NGS panels include copy number analysis in order to provide the most clinically sensitive testing possible. Our complete offering guarantees coverage of all pathogenic variants in the most relevant genes.

Comprehensive Epilepsy Panel

Comprehensive Muscular Dystrophy/Myopathy Panel

 

Comprehensive Intellectual Disabilty Panel

Ataxia/Episodic Ataxia Panel

Spastic Paraplegia Panel

We strive to give you the best answers possible when you trust us with your patients’ samples and endeavor to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.

Expanded SCA Repeat Expansion Testing Now Available

Approximately 50-80% of ataxia cases are caused by repeat expansions, which are not detected by standard sequencing analysis. We recently launched the addition of the 5 most common SCA repeat expansions into our Ataxia/Episodic Ataxia Panels to meet this need. To further support our comprehensive ataxia options and provide the most sensitive testing possible, MNG Laboratories has further expanded our SCA repeat expansion portfolio to include SCAs 8, 10, 12, 17, 36 and DRPLA. MNG Laboratories is proud to announce the launch of 3 new tests: We also went ahead and updated two of our existing NGS panels to reflect our expanded SCA portfolio:   We strive to give you the best answers possible when you trust us with your patients’ samples. MNG constantly endeavors to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.

New Panels Now Available

MNG Laboratories is excited to announce the release of 3 new panels to our testing portfolio. Each panel includes single-exon resolution copy number analysis to ensure that we are providing you with the most clinically sensitive testing possible. We also understand that pathogenic variants in the mitochondrial DNA (mtDNA) can be associated with an array of clinical presentations and mtDNA analysis is often overlooked when ordering genetic testing. That is why we include mtDNA sequencing and deletion testing in our relevant next-generation sequencing panels at no additional charge. NGS428: Tuberous Sclerosis Panel (2 Genes) Tuberous sclerosis (TSC) is a rare genetic disease causing benign tumors to grow in the brain and other vital organs such as kidneys, eyes, lungs, ears, and heart. Symptoms may present as seizures, mental retardation, and skin abnormalities. Heterozygous pathogenic variants can be found in 75%-90% of individuals who meet the clinical diagnostic criteria for TSC. Of the patients that are diagnosed with TSC, 31% are found to have pathogenic variants in the TSC1 gene and 69% in the TSC2 gene. NGS429:  Familial Hemiplegic Migraine Panel (5 Genes + mtDNA)  Familial Hemiplegic Migraine (FHM) is a dominantly inherited form of migraine characterized by intense, throbbing pain in one area of the head, often preceded by aura and accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Most individuals diagnosed with FHM have an affected parent. FHM is often earlier in onset than typical migraine. Approximately 40%-50% of patients have cerebellar signs ranging from nystagmus to progressive mild ataxia. NGS430: Stroke Panel (29 Genes + mtDNA) Stroke has a significant impact on patients, families and our healthcare system. It is the third largest cause of death, causing an estimated 10% of all deaths worldwide. Although many risk factors exist and contribute to the incidence of stroke, genetics can account for up to 50% of an individual’s risk of developing a stroke in the future. We strive to give you the best answers possible when you trust us with your patients’ samples. MNG constantly endeavors to provide you with actionable results. Utilizing our proprietary Genome MaNaGer™ pipeline and Neurogenetic Answers™ reporting process, we aim to reduce the distraction of unrelated variants of uncertain significance.

Build Your Own Custom Next-Generation Sequencing Panel

MNG Laboratories’ testing portfolio isn’t just limited to what we have in our test directory.

We understand that everyone has different testing needs, which is why we are now offering the flexibility of customizing targeted next-generation sequencing (NGS) panels. Additional testing such as repeat expansions and mtDNA sequencing and deletion analysis are also available as an add on in order to increase clinical sensitivity. For guaranteed results in less than 2 weeks, we also provide a STAT option. For more information, including gene selection, additional options, and pricing, please contactMNG Laboratories and we will help you customized your next NGS panel.